The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
| Weiss Ratings | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.69 | |||
| Price History | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -25.10% | |||
| 30-Day Total Return | 9.82% | |||
| 60-Day Total Return | 240.95% | |||
| 90-Day Total Return | 118.29% | |||
| Year to Date Total Return | 144.04% | |||
| 1-Year Total Return | -58.13% | |||
| 2-Year Total Return | -51.29% | |||
| 3-Year Total Return | -86.89% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -67.78% | |||
| 52-Week Low % Change | 398.80% | |||
| Price | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.94 | |||
| 52-Week Low Price | $0.13 | |||
| 52-Week Low Price (Date) | Nov 21, 2024 | |||
| 52-Week High Price (Date) | Mar 15, 2024 | |||
| Valuation | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 47.22M | |||
| Enterprise Value | 122.77M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.78 | |||
| Earnings Per Share Growth | -14.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.12 | |||
| Price/Book (Q) | 3.05 | |||
| Enterprise Value/Revenue (TTM) | 0.32 | |||
| Price | $0.72 | |||
| Enterprise Value/EBITDA (TTM) | -2.14 | |||
| Enterprise Value/EBIT | -1.93 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 75.52M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 562 735 3226 | |||
| Address | 18000 Studebaker Road Cerritos, CA 90703 | |||
| Website | theoncologyinstitute.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -16.78% | |||
| Profit Margin | -18.53% | |||
| Management Effectiveness | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.99% | |||
| Return on Equity | -- | |||
| Income Statement | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 378.93M | |||
| Total Revenue (TTM) | 378.93M | |||
| Revenue Per Share | $5.02 | |||
| Gross Profit (TTM) | 53.74M | |||
| EBITDA (TTM) | -57.43M | |||
| EBIT (TTM) | -63.59M | |||
| Net Income (TTM) | -70.24M | |||
| Net Income Avl. to Common (TTM) | -70.24M | |||
| Total Revenue Growth (Q YOY) | 21.78% | |||
| Earnings Growth (Q YOY) | 7.50% | |||
| EPS Diluted (TTM) | -0.78 | |||
| EPS Diluted Growth (Q YOY) | 7.31% | |||
| Balance Sheet | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 47.40M | |||
| Cash Per Share (Q) | $0.63 | |||
| Total Current Assets (Q) | 116.43M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 15.48M | |||
| Current Ratio (Q) | 2.490 | |||
| Book Value Per Share (Q) | $0.20 | |||
| Total Assets (Q) | 179.18M | |||
| Total Current Liabilities (Q) | 46.76M | |||
| Total Debt (Q) | 122.95M | |||
| Total Liabilities (Q) | 163.70M | |||
| Total Common Equity (Q) | 15.48M | |||
| Cash Flow | TOI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 59.59M | |||
| Cash from Financing (TTM) | -5.11M | |||
| Net Change in Cash (TTM) | 19.87M | |||
| Levered Free Cash Flow (TTM) | -12.22M | |||
| Cash from Operations (TTM) | -34.62M | |||
